scientific article; zbMATH DE number 2242805
From MaRDI portal
Publication:5714616
zbMATH Open1079.62103MaRDI QIDQ5714616FDOQ5714616
Authors: B. Nebiyou Bekele, Yu Shen 
Publication date: 3 January 2006
Title of this publication is not available (Why is that?)
Recommendations
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Bayesian joint modeling of chemical structure and dose response curves
- A Bayesian Approach to Dose-Response Assessment and Synergy and Its Application to In Vitro Dose-Response Studies
- Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials
- Multivariate Markov models for the conditional probability of toxicity in phase II trials
- Bayesian experimental design for a toxicokinetic-toxicodynamic model
- Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity
- scientific article; zbMATH DE number 1136421
- A Bayesian nonparametric modeling framework for developmental toxicity studies
- Bayesian hierarchical analysis for multiple health endpoints in a toxicity study
Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10)
Cited In (21)
- Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials
- TITE-gBOIN-ET: time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes
- Optimization in a multivariate generalized linear model situation
- Optimizing the concentration and bolus of a drug delivered by continuous infusion
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials
- REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors
- Change-point joint model for identification of plateau of activity in early phase trials
- A semiparametric Bayesian approach to population finding with time‐to‐event and toxicity data in a randomized clinical trial
- A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications
- CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome
- Hybrid design evaluating new biomarkers when there is an existing screening test
- A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials
- Review and Comparison of Computational Approaches for Joint Longitudinal and Time‐to‐Event Models
- A Bayesian approach for generalized linear models with explanatory biomarker measurement variables subject to detection limit: an application to acute lung injury
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
- A Bayesian Approach to Dose-Response Assessment and Synergy and Its Application to In Vitro Dose-Response Studies
- Adaptive designs for selecting drug combinations based on efficacy-toxicity response
- Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
This page was built for publication:
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5714616)
